Propofol-Lipuro

The exact B. Braun 10 mg/ml MCT/LCT emulsion and both Georgian packs have current sourced human authorisations and a current official regulator RCP. A separate current 10 mg/ml veterinary propofol emulsion is authorised for IV induction and short maintenance in dogs and cats. The exact human product remains off-label and has no located veterinary trial of its specific excipient system.

Direct clinical evidence in 290 dogs and the current veterinary label consistently support rapid IV induction, incremental short maintenance or transition to inhalational anaesthesia, with usually smooth recovery. A 2024 randomized clinical study confirmed effective induction and broadly similar early haemodynamics to alfaxalone, although propofol caused a short MAP reduction and fixed dosing was inadequate for intubation in 2/14 dogs. Dose must therefore be titrated to effect and reduced after premedication.

Transient apnoea and hypotension are predictable, sometimes intervention-requiring induction risks, but are manageable in the defined equipped setting with titration, airway control and monitoring. Current comparative data found hypotension in 3/12 propofol dogs. Short use is well characterised; prolonged infusion is outside scope because recent cases associate 76-131 hours of exposure with oxidative red-cell injury and Heinz-body anaemia.

The ready-to-use 10 mg/ml emulsion needs no reconstitution, has rapid onset, is easily titrated through an IV catheter and usually permits quick transition to inhalational maintenance. The 20 ml ampoule suits many canine inductions; larger patients may need multiple ampoules. Strict asepsis, immediate airway readiness, continuous monitoring and disposal of unused single-patient emulsion are mandatory but normal burdens in an anaesthesia service.

The exact B. Braun 10 mg/ml MCT/LCT emulsion and both Georgian packs have current sourced human authorisations and a current official regulator RCP. A separate current 10 mg/ml veterinary propofol emulsion is authorised for IV induction and short maintenance in dogs and cats. The exact human product remains off-label and has no located veterinary trial of its specific excipient system.

Direct clinical evidence in 207 cats and the current veterinary label consistently support rapid IV induction, short incremental maintenance and usually smooth recovery. Feline dose requirements are higher than in dogs and recovery becomes materially slower with longer administration; efficacy remains strong for the deliberately short scope, provided the dose is titrated to effect and reduced after premedication.

Transient apnoea and hypotension are predictable induction risks and cats showed apnoea in both the large clinical cohort and repeat-dose studies. Short monitored exposure is generally well tolerated, but cats have slower recovery after prolonged administration and a species-relevant oxidative red-cell risk: small studies often found only low Heinz-body counts, while a clinical anaemia case occurred after 12 repeated inductions. This makes serial or prolonged use a separate, less favourable decision.

The ready-to-use 10 mg/ml emulsion is rapidly titratable and a 20 ml ampoule is ample for most feline inductions. Small incremental volumes are measurable with an appropriate syringe, but IV access, strict asepsis, airway/ventilation readiness, continuous monitoring and disposal of the unused single-patient remainder are essential. Longer maintenance becomes less practical because feline recovery slows.